Education
About Us
Working with TipRanks
Follow Us
PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Stock Chart & Stats
$5.52
-$0.11(-3.01%)
At close: 4:00 PM EST
$5.52
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$0.88 - $6.72
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$379.49M
Enterprise Value-$20.44M
Total Cash (Recent Filing)$163.66M
Total Debt (Recent Filing)$17.44M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 19, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding68,748,220
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-1.44
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.43
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$11.00Price Target Upside99.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DifferentiationPepGen is positioning itself to differentiate clinically by focusing on broader functional outcomes, such as GI function, 10-meter walk, balance, swallowing, and pulmonary measures.
Patent ProtectionPepGen’s newly issued U.S. patent secures long-term exclusivity for PGN-EDODM1, reinforcing the durability of its DM1 franchise.
Splicing CorrectionThe FREEDOM2 multiple ascending dose trial is progressing, with data expected to be promising based on the robust 54% mean splicing correction achieved in the single dose FREEDOM trial.
Bears Say
Development CompetitionPEPG is behind competitors in development, and it remains unclear if an accelerated path will be open.
Renal Biomarker ConcernsOne patient experienced a transient, reversible renal biomarker elevation, indicating that the program might not be out of the woods yet.
Safety Profile ConcernsClarity on the safety profile of PEPG’s proprietary EDO platform is still needed, given the readthrough risk from the discontinued DMD program.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $0.88 and its highest was $6.72 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $379.49M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is Mar 19, 2026 which is in 90 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Nov 12, 2025. The company reported -$0.52 earnings per share for the quarter, beating the consensus estimate of -$0.565 by $0.045.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.35.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 68,748,220 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.52 in its last earnings report, beating expectations of -$0.565. Following the earnings report the stock price went up 10.323%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (99.28% Upside)
$11.00 (99.28% Upside)
Hedge Fund Trend
Increased
By 13.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $30.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 9.1%
Last 30 Days ▲ 9.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-62.25%
Trailing 12-Months
Asset Growth
-47.16%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc. (PEPG) is a biotechnology company focused on developing transformative therapies for patients with neuromuscular and neurological diseases. Leveraging its proprietary Enhanced Delivery Oligonucleotide (EDO) platform, PepGen aims to deliver innovative solutions that improve the delivery and efficacy of oligonucleotides. The company's core products are designed to address unmet medical needs through targeted treatments that can enhance the quality of life for patients suffering from debilitating conditions.
PEPG Stock 12 Month Forecast
Average Price Target
$11.00
▲(99.28% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
I-MAB
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---